Contribute Try STAT+ Today

Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like a pleasant morning to lift the spirits. A cool breeze and warm sun are enveloping the Pharmalot campus as we hunker down and sift through our ever-growing to-do list. A familiar exercise, yes? Well, time to get cracking. So please join us for a daily ritual — a few cups of stimulation — and do keep us in mind if you hear something fascinating. Meanwhile, here are your tidbits. Dig in and have a grand day. …

Pfizer (PFE) significantly increased revenue projections from its Covid-19 vaccine for the year, as sales from the shot over the first three months of 2021 lifted the company to a stronger quarterly profit, The Wall Street Journal says. The vaccine contributed $3.5 billion in revenue in the first three months of 2021 as the U.S. vaccination campaign kicked into high gear. Over the course of the full year, Pfizer now expects the vaccine to generate $26 billion in sales, up from an earlier forecast of $15 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.